The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...